<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383627</url>
  </required_header>
  <id_info>
    <org_study_id>17-0531</org_study_id>
    <nct_id>NCT03383627</nct_id>
  </id_info>
  <brief_title>Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease</brief_title>
  <official_title>Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes control is often assessed by tests of glucose levels over time, such as the
      glycosylated hemoglobin A1c (HbA1c) and fructosamine. In the later stages of chronic kidney
      disease (CKD) there is limited data available on the utility of these tests. There are
      reasons to believe that the tests may be less accurate in this population. Continuous glucose
      monitoring (CGM) offers an effective method for understanding the totality of glucose
      exposure and incidence of both hyperglycemic and hypoglycemic excursions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the proposed study Investigator plan to utilize CGM in patients with late stage CKD stages
      3b-5 to 1) determine accuracy of HbA1c and serum fructosamine testing as measures of glucose
      control in patients with Type 2 Diabetes Mellitus (T2DM), 2) Better understand test
      characteristics in the late stage CKD population (correlation, linear equation, slope, Y
      intercept, average glucose at different HbA1c levels), 3) Develop a preliminary understanding
      of how test characteristics differ in late stage CKD compared to other patients with
      diabetes, 4) quantify time burden and number of episodes of hypoglycemia, 4) study
      hyperglycemic burden and 5) analyze glucose variability. The research staff will explain the
      study to patients that meet all inclusion criteria. Patients will get time to understand the
      study, review the consent document, ask questions to the PI, and then provide their consent
      to participate in the study. On Day 1 of the study, a CGM (Freestyle Libre) device will be
      placed on patients with CKD 3b-5 which will be worn for 14 consecutive days. Patients will
      return on Day 14 to remove the CGM device. HbA1c and fructosamine values will be drawn on Day
      14 and these results will be compared with average glucose monitoring values as recorded on
      the CGM device. Incidence, duration, and severity of both hypoglycemic and hyperglycemic
      events will be analyzed. Investigators hypothesis that there will be significant variability
      in the serum HbA1c values when compared with calculated HbA1c from CGM readings.
      Investigators also hypothesize that the results will reflect a greater incidence of
      hypoglycemia in this population by CGM analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Glucose Concentration Measured by CGM</measure>
    <time_frame>14 Days</time_frame>
    <description>Mean glucose concentration (mg/dL) will be measured using measurements taken by CGM device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypoglycemic Events</measure>
    <time_frame>14 Days</time_frame>
    <description>Hypoglycemic event will be considered when blood sugar level is &lt;=70 mg/dl. Detail information like time of event, number of subjects with an event, duration of event will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Number of Hypoglycemic Events Per Participant.</measure>
    <time_frame>14 Days</time_frame>
    <description>Total number of hypoglycemic events per subject will be calculated during the study period. Mean number of events per subject will be analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration Hypoglycemic Events</measure>
    <time_frame>14 Days</time_frame>
    <description>As monitoring device measures blood glucose level numerous time, duration of hypoglycemic event will be calculated in percent time per subject based on total duration of time subject wore CGM device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean HbA1c</measure>
    <time_frame>14 Days</time_frame>
    <description>HbA1c collected at end of the participation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Fructosamine Concentration</measure>
    <time_frame>14 Days</time_frame>
    <description>Serum fructosamine (µmol/L) collected at the end of participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Serum Fructosamine</measure>
    <time_frame>14 days</time_frame>
    <description>Using blood glucose information measured with continuous blood glucose monitoring device, probable level of serum fructosamine (µmol/L) will be measured for each participant and mean will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Continuous glucose monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring</intervention_name>
    <description>The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.
CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.
Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis.</description>
    <arm_group_label>Continuous glucose monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older with ability to speak and understand English

          -  Established diagnosis of type 2 Diabetes Mellitus

          -  Chronic Kidney Disease (stages 3b, 4 or 5, eGFR (Glomerular Filtration Rate) &lt; 45
             ml/min, and not on dialysis) documented within 3 months of enrollment

        Exclusion Criteria:

          -  Type 2 Diabetes Mellitus.

          -  Patient with End stage kidney disease on Dialysis.

          -  Presence of Hemoglobinopathies.

          -  Red blood cell transfusion in the last 12 weeks.

          -  Hb &lt; 9 g/dL documented within 3 months of enrollment - Dosing with an erythropoiesis
             stimulating agent is acceptable but dose must be stable for two months.

          -  Use of acetaminophen on a daily basis.

          -  Systemic steroid treatment in the past 12 weeks.

          -  Greater than 50% dose change in diabetes medications or new diabetes medications
             started in the previous 8 weeks.

          -  Currently pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubaina Presswala, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwell Health (Division Endocrinology and Nephrology)</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miedema K. Standardization of HbA1c and Optimal Range of Monitoring. Scand J Clin Lab Invest Suppl. 2005;240:61-72.</citation>
    <PMID>16112961</PMID>
  </reference>
  <reference>
    <citation>Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984 Sep;27(3):351-7. Review.</citation>
    <PMID>6389240</PMID>
  </reference>
  <reference>
    <citation>Castellino P, DeFronzo RA. Glucose metabolism and the kidney. Semin Nephrol. 1990 Sep;10(5):458-63. Review.</citation>
    <PMID>2236987</PMID>
  </reference>
  <reference>
    <citation>Dolscheid-Pommerich RC, Kirchner S, Weigel C, Eichhorn L, Conrad R, Stoffel-Wagner B, Zur B. Impact of carbamylation on three different methods, HPLC, capillary electrophoresis and TINIA of measuring HbA1c levels in patients with kidney disease. Diabetes Res Clin Pract. 2015 Apr;108(1):15-22. doi: 10.1016/j.diabres.2015.01.034. Epub 2015 Jan 29.</citation>
    <PMID>25684605</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>January 23, 2020</results_first_submitted>
  <results_first_submitted_qc>January 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2020</results_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Lubaina Presswala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to study data will be limited to Institutional Review Board (IRB) approved personnel only.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03383627/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Glucose Monitoring</title>
          <description>If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous Glucose Monitoring</title>
          <description>If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of Chronic Kidney Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diabetes Mellitus Type 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Maliganancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 to &lt;=15 mL/min</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;15 to &lt;=30 mL/min</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;30 to &lt;=45 mL/min</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=25</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;25 to &lt;=30</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;30 to &gt;=35</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;35</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Glucose Concentration Measured by CGM</title>
        <description>Mean glucose concentration (mg/dL) will be measured using measurements taken by CGM device.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Concentration Measured by CGM</title>
          <description>Mean glucose concentration (mg/dL) will be measured using measurements taken by CGM device.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" lower_limit="75" upper_limit="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypoglycemic Events</title>
        <description>Hypoglycemic event will be considered when blood sugar level is &lt;=70 mg/dl. Detail information like time of event, number of subjects with an event, duration of event will be analyzed.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypoglycemic Events</title>
          <description>Hypoglycemic event will be considered when blood sugar level is &lt;=70 mg/dl. Detail information like time of event, number of subjects with an event, duration of event will be analyzed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Number of Hypoglycemic Events Per Participant.</title>
        <description>Total number of hypoglycemic events per subject will be calculated during the study period. Mean number of events per subject will be analyzed.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Hypoglycemic Events Per Participant.</title>
          <description>Total number of hypoglycemic events per subject will be calculated during the study period. Mean number of events per subject will be analyzed.</description>
          <units>Hypoglycemic events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration Hypoglycemic Events</title>
        <description>As monitoring device measures blood glucose level numerous time, duration of hypoglycemic event will be calculated in percent time per subject based on total duration of time subject wore CGM device.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Duration Hypoglycemic Events</title>
          <description>As monitoring device measures blood glucose level numerous time, duration of hypoglycemic event will be calculated in percent time per subject based on total duration of time subject wore CGM device.</description>
          <units>Percentage time with Hypoglycemia</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean HbA1c</title>
        <description>HbA1c collected at end of the participation.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean HbA1c</title>
          <description>HbA1c collected at end of the participation.</description>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="4.8" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Fructosamine Concentration</title>
        <description>Serum fructosamine (µmol/L) collected at the end of participation.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Fructosamine Concentration</title>
          <description>Serum fructosamine (µmol/L) collected at the end of participation.</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.1" lower_limit="177" upper_limit="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determination of Serum Fructosamine</title>
        <description>Using blood glucose information measured with continuous blood glucose monitoring device, probable level of serum fructosamine (µmol/L) will be measured for each participant and mean will be analyzed.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Glucose Monitoring</title>
            <description>Subjects enrolled and wearing CGM device</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Serum Fructosamine</title>
          <description>Using blood glucose information measured with continuous blood glucose monitoring device, probable level of serum fructosamine (µmol/L) will be measured for each participant and mean will be analyzed.</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.1" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over the period of study participation (Up to 14 days from date of enrollment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuous Glucose Monitoring</title>
          <description>If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.
Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.
There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.
Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size of 80 patients were predominately male and non-Hispanic. It would also have been meaningful to have more robust data of a diary of self-reported symptoms during the 14 day period.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lubaina Presswala, DO</name_or_title>
      <organization>Northwell Health</organization>
      <phone>516-708-2540</phone>
      <email>lpresswala@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

